See more : Tempest Minerals Limited (TEM.AX) Income Statement Analysis – Financial Results
Complete financial analysis of 23andMe Holding Co. (ME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 23andMe Holding Co., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Zhong Nong Yuan Fang Holdings, Inc. (ANAS) Income Statement Analysis – Financial Results
- Warburg Pincus Capital Corporation I-A (WPCA-WT) Income Statement Analysis – Financial Results
- Oak View Bankshares, Inc. (OAKV) Income Statement Analysis – Financial Results
- Federal Realty Investment Trust (FRT) Income Statement Analysis – Financial Results
- Public Storage (PSA-PI) Income Statement Analysis – Financial Results
23andMe Holding Co. (ME)
About 23andMe Holding Co.
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 219.64M | 299.49M | 271.89M | 243.92M | 305.46M | 440.90M |
| Cost of Revenue | 120.26M | 164.99M | 138.95M | 126.91M | 168.03M | 257.91M |
| Gross Profit | 99.38M | 134.50M | 132.95M | 117.01M | 137.43M | 182.99M |
| Gross Profit Ratio | 45.25% | 44.91% | 48.90% | 47.97% | 44.99% | 41.50% |
| Research & Development | 205.36M | 222.60M | 189.38M | 159.86M | 181.28M | 140.53M |
| General & Administrative | 148.33M | 115.98M | 97.38M | 99.15M | 59.39M | 50.29M |
| Selling & Marketing | 85.60M | 119.93M | 100.34M | 43.20M | 110.52M | 190.85M |
| SG&A | 205.74M | 235.91M | 197.72M | 142.35M | 169.91M | 231.24M |
| Other Expenses | 9.63M | -93.00K | -83.00K | 1.32M | 1.34M | 0.00 |
| Operating Expenses | 420.73M | 458.51M | 387.10M | 302.20M | 351.19M | 371.77M |
| Cost & Expenses | 540.99M | 623.50M | 526.05M | 429.12M | 519.22M | 629.68M |
| Interest Income | 14.33M | 9.68M | 277.00K | 1.58M | 6.24M | 5.25M |
| Interest Expense | 0.00 | 0.00 | 277.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 29.48M | 36.50M | 26.15M | 20.25M | 22.25M | 9.90M |
| EBITDA | -291.87M | -291.94M | -228.01M | -164.95M | -191.51M | -173.63M |
| EBITDA Ratio | -132.89% | -96.00% | -95.99% | -67.62% | -47.72% | -40.57% |
| Operating Income | -321.36M | -324.01M | -254.15M | -185.20M | -213.76M | -188.78M |
| Operating Income Ratio | -146.31% | -108.19% | -93.48% | -75.92% | -69.98% | -42.82% |
| Total Other Income/Expenses | -345.28M | 9.58M | 33.18M | 1.58M | -37.11M | 5.25M |
| Income Before Tax | -666.63M | -314.43M | -220.97M | -183.62M | -250.86M | -183.53M |
| Income Before Tax Ratio | -303.51% | -104.99% | -81.27% | -75.28% | -82.13% | -41.63% |
| Income Tax Expense | 73.00K | -2.77M | -3.48M | -255.00K | 38.45M | 9.74M |
| Net Income | -666.70M | -311.66M | -217.49M | -183.36M | -289.31M | -183.53M |
| Net Income Ratio | -303.55% | -104.06% | -79.99% | -75.17% | -94.71% | -41.63% |
| EPS | -1.40 | -13.81 | -9.96 | -9.04 | -12.34 | -9.03 |
| EPS Diluted | -28.01 | -13.81 | -9.96 | -9.04 | -12.34 | -9.03 |
| Weighted Avg Shares Out | 475.98M | 22.58M | 21.83M | 20.32M | 20.32M | 20.32M |
| Weighted Avg Shares Out (Dil) | 23.80M | 22.58M | 21.83M | 20.32M | 20.32M | 20.32M |
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
Direct-to-Consumer (DTC) Genetic Testing Business Report 2023-2030 with Focus on 80+ Players Including 23andMe, Ancestry.com, Chengdu 23Mofang Biotechnology, and DirectLabs
23andMe Holding Co (NASDAQ: ME) Jewish and Chinese Users
23andMe Data Breach - Hackers Targeted Jewish and Chinese Users Data
23andMe rejects CEO Anne Wojcicki's take-private offer
Levi & Korsinsky Reminds 23andMe Consumers of an Investigation into Recent Data Breach
ME Stock Alert: CEO Anne Wojcicki Enters $200 Million Buyout Offer for 23andMe
23andMe rejects CEO Wojcicki take-private offer
23andMe Special Committee responds to CEO's take-private proposal
23andMe CEO Wojcicki makes offer to take the firm private, filing shows
Source: https://incomestatements.info
Category: Stock Reports